Njengamanje, i-COVID-19 isesimeni esiwubhubhane emhlabeni jikelele. Ukuma okuphezulu kwezinhlobonhlobo ze-Delta ne-Omicron kugcwele, okuholela ekuthuthukisweni okuqhubekayo kwekhono lazo lokudlulisela. Phakathi kwamagagasi aphindaphindiwe e-COVID-19, ngaphezu komgomo we-COVID-19, ukuthuthukiswa kwemithi yomlomo esebenzayo ye-COVID-19 kanye nezindlela zokuhlola ezisheshayo, ezilula neziqanjiwe nakho sekube yisidingo esisha sokuvimbela nokulawula ubhubhane lwamanje. I-Viva Biotech Holdings ne-XLement, etshalwe futhi yafakwa yi-Viva BioInnovator, izibophezele ekukhiqizeni izidakamizwa eziphuzwayo ze-COVID-19 kanye nokuhlolwa kwegciwane, okubambe iqhaza ekulweni nobhubhane lwe-COVID-19.
Isivumelwano seLanghua Pharmaceutical ne-MPP sokukhiqiza isithako esingavuthiwe somuthi we-COVID-19 we-antiviral molnupiravir.
Jan 2022, i-Medicines Patent Pool (MPP) yamemezela ukuthi isisayine izivumelwano nezinkampani eziningana ezikhiqiza amajenerikhi okuhlanganisa i-Zhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), inkampani engaphansi kwe-Viva biotech holdings (Viva Biotech (01873.HK)) ukwenziwa komuthi we-antiviral we-COVID-19 we-molnupiravir futhi uhlinzeke emazweni angu-105 anemali ephansi naphakathi (ama-LMIC) ukuze kube lula ukufinyelela okufinyelelekayo emhlabeni jikelele kwe-molnupiravir futhi kusekelwe ukuvimbela nokulawula ubhubhane lwasekhaya. Izinkampani ezinhlanu zizogxila ekukhiqizeni izithako ezingavuthiwe, izinkampani ezingu-13 zizokhiqiza kokubili isithako esingavuthiwe kanye nomuthi oqediwe kanti izinkampani ezingu-9 zizokhiqiza umuthi osuphelile.
I-Medicines Patent Pool (MPP) yinhlangano yezempilo yomphakathi esekelwa yiZizwe Ezihlangene esebenzela ukukhulisa ukufinyelela, nokwenza lula ukuthuthukiswa kwemithi esindisa impilo yamazwe anemali engenayo ephansi kanye nemaphakathi. I-MPP kanye ne-MSD, igama lokuhweba le-Merck & Co., Inc Kenilworth NJ USA basayine isivumelwano selayisense ngokuzithandela ngo-Oct 2021. Ngaphansi kwemibandela yesivumelwano, i-MPP, ngelayisensi enikezwe yi-MSD, izovunyelwa ukuthi iqhubekisele phambili ilayisensi engakhethekile. amalayisense kubakhiqizi (“Ilayisensi ye-MPP”) futhi kuhlukanise isisekelo sokukhiqiza ukuze kunikezwe i-molnupiravir eqinisekiswe ikhwalithi emazweni ambozwe Ilayisensi ye-MPP, kuncike ekugunyazweni kokulawula kwendawo.
I-Molnupiravir (MK-4482 kanye ne-EIDD-2801) iwuhlobo lophenyo, olulawulwa ngomlomo lwe-analog ye-ribonucleoside enamandla evimbela ukuphindaphinda kwe-SARS-CoV-2 (i-ejenti eyimbangela ye-COVID-19). I-Molnupiravir i-MSD eyakhayo ngokubambisana ne-Ridgeback Biotherapeutics, iwumuthi wokuqala womlomo wokuvimbela amagciwane otholakalayo wokwelapha i-COVID-19. Idatha evela kuSigaba 3 I-MOVe-OUT ibonise ukuthi ukwelashwa kusenesikhathi nge-molnupiravir kwehlisa kakhulu ingcuphe yokulaliswa esibhedlela noma yokushona engozini enkulu, abantu abadala abangagonyiwe abane-COVID-19.
Ngokusho kwe-MPP, izinkampani ezanikezwa amalayisense amancane zabonisa ngempumelelo amandla azo okuhlangabezana nezidingo ze-MPP ezihlobene namandla okukhiqiza, ukuthobela imithetho, kanye nekhono lokuhlangabezana namazinga omhlaba emithi eqinisekiswa yikhwalithi. Ukugunyazwa okunikezwe i-Langhua Pharmaceutical yi-MPP kumele ukuqinisekiswa okuphezulu nokuqashelwa ekuthuthukisweni kwenqubo yayo kanye nokukhulisa ama-API, ukusimama kokuhlinzeka, i-GMP kanye nohlelo lwe-EHS.
Ikhithi Yokuhlola ye-Xlement's COVID-19 Iphumelele Ukuhlolwa Komnyango Wesayensi Nobuchwepheshe wasePeople's Republic of China
Ngomhla zi-2 kuNdasa, 2022, u-Xlement, inkampani ezinikele ye-NanoSPR biochip kanye nezinsimbi ze-biotech eyatshala imali ngaphambilini futhi yafukanyelwa yi-Viva BioInnovator, yathola isaziso sokudlulisa ukuhlolwa kokusebenza ku-Ministry of Science and Technology of the People's Republic of China. Iphrojekthi yayo ethi “R&D and Mass Production ye-NanoSPR COVID-19 Particle Test Kit” ingenye yamaphrojekthi abalulekile “wohlelo Lokuvinjelwa Nokulawulwa Kwengozi Yezokuphepha Komphakathi kanye Nobuchwepheshe Bezimo Eziphuthumayo Nezisetshenziswa” olunikeza ingxenye ebalulekile ku-COVID-19- ucwaningo lwesayensi oluhlobene oluqhubekayo eShayina. Ngokuphumelela kwayo ekuhlolweni, Ikhithi Yokuhlola ye-Xlement's COVID-19 nayo isigunyazwe yi-European Union CE ukuze ikhiqize ngobuningi besikhathi esizayo futhi izoqala ukusetshenziswa maduze.
Isebenzisa ubuchwepheshe be-chip ye-NanoSPR obuyingqayizivele, i-Xlement ithuthukise ikhithi yokuhlola yezinhlayiya ze-COVID-19, evumela ukuhlolwa kwesinyathelo esisodwa sama-antigen amaningi amagciwane kumasampula angama-96 kungakapheli imizuzu eyi-15, futhi ukuzwela kuseduze nokuhlola i-antigen eyodwa. Le ndlela ibonisa izinzuzo ezinkulu uma kuqhathaniswa namasu okuhlola i-viral nucleic acid ekhona: ingasetshenziselwa ukuzihlola ekhaya, inciphisa isikhathi sokuhlola ngokuphawulekayo, ngaleyo ndlela, inciphisa kakhulu izindleko zokuhlola ama-reagents kanye nomsebenzi. Ngokwamukelwa okwengeziwe kobuchwepheshe be-NanoSPR ekuhlolweni kwe-COVID-19 okuthuthukiswe yi-Xlement, silindele ukubona ukuxilongwa okushesha kakhudlwana kwamasampuli asolwayo kanye nokuhlolwa ngokushesha esizeni ngezinga elikhulu.